Compare Nvidia Corp (NVDA) vs Sanofi SA (SNY) Price & Performance

Nvidia CorpTrade

Sanofi SATrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs Sanofi SA — how do they compare? Nvidia Corp trades at $206.4 (market cap $4.92T), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Nvidia Corp is far larger — about 46.9× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.

	NVDA	SNY
Market Cap	$4.92T	$104.83B
Sector	Technology	Health
52-Week High	$235.75	$52.34
52-Week Low	$165.17	$41.33
Enterprise Value	$4.86T	$121.32B
Dividend Yield	0.49%	5.5%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

NVIDIA (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamentals. Recent earnings beats and robust profitability margins highlight operational strength. The stock is supported by a consensus analyst price target of $325.86, though it faces technical resistance near $210.

Outlook remains positive driven by AI chip demand, but risks include competition and market volatility. Revenue growth acceleration and high institutional ownership suggest long-term potential, yet valuation multiples require sustained execution to justify further upside.

Sanofi SA

SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.

Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVDA

Amplify CWP Growth & Income ETF offers 10.69% yield with tech focus, rated a BUY for income portfolios.Seeking Alpha · 8 hours agoBullish Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 9 hours agoNeutral Nvidia faces pressure from cheaper Chinese chips but bets on AI and emerging tech for growthSeeking Alpha · 10 hours agoNeutral View details →

SNY

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026GlobeNewsWire · 12 hours agoNeutral View details →

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.